fda compounding semaglutide enforcement news november 2025 Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines FDA's GLP-1 decision kicks off
Description
New Zealand | In depth: The people who were first in line might not be the people who urgently need it Researchers noticed in diabetes trials that patients on semaglutide were losing significant amounts of weight, so Novo Nordisk, the company that owns Ozempic, began testing the drug for indications of weight loss specifically
For GLP-1s, there is limited evidence supporting doses lower than those studied in clinical trials
Among them is insulin resistance, a condition wherein your body does not efficiently use insulin, which can lead to increased hunger and other symptoms
Can you lose muscle while losing weight on a GLP-1
What results can you expect in the first 4-8 weeks of strength training on a GLP-1
